Estudo comparativo do uso de Medetomidina e Xilazina em gatos e sua reversão com Atipamezole

Abstract

The medetomidine is sedative and analgesic of the group of the a2 adrenergic agonist approved for dogs and cats, described now as more potent than the xylazine, an old agonist a2 adrenergic of veterinary use. The main difference among those two agonists is the selectivity to the receptors a2-adrenergics, being the medetomidine considered more selective, checking, therefore, larger sedative and analgesic potency. The reversion of the effects of a2-adrenergics is accomplished with the use of the a2-adrenergics antagonists, being the atipamezole the most efficient due to his largest selectivity. The objective of this work was to accomplish a comparative study of the effects of the medetomidine and xylazine in cats, and to prove the reversion of the induced effects of these two agonists with atipamezole. It was concluded that the medetomidine and the xylazine present similar effects in most of the appraised parameters, however the medetomidina induced hyperglycemia and sedation more accentuated than the xylazine. The atipamezole presented excellent effectiveness, antagonizing all of the effects induced by the medetomidine and the xylazine.